Treat Heart Failure!

On February 23, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Xinlitai Pharmaceutical has launched a Phase 3 clinical study of S086 tablets in the treatment of patients with heart failure with reduced ejection fraction (HFrEF), and plans to enter the drug in China.

Screenshot source: Drug Clinical Trial Registration and Information Publicity Platform

Heart failure is a common and incurable serious chronic disease caused by many reasons

According to the public information of Xinlitai Pharmaceutical, S086 tablet is an angiotensin receptor enkephalinase inhibitor (ARNI) small molecule chemical drug

According to the literature, many guidelines for the diagnosis and treatment of heart failure have adopted ARNIs as the first-line drugs for the treatment of heart failure

According to the China Clinical Trial Registration and Information Publicity Platform, there are currently two Phase 3 clinical trials underway for S086 tablets, one of which is a multi-center evaluation of the efficacy and safety of S086 tablets in the treatment of mild to moderate essential hypertension.

The other is a randomized, double-blind, parallel-controlled, multi-center phase 3 clinical study of S086 tablets for heart failure with reduced ejection fraction

We look forward to the smooth progress of the clinical trials of Xinlitai Pharmaceutical S086 tablets in China, which will benefit more patients as soon as possible

References:

[1] China Drug Clinical Trial Registration and Information Publicity Platform.

[3] Xin Litai 2021 Semi-annual Report.

[4] Jia Lingmei et al.